RT @Biotech2050: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Esc…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma {in mice} [Sep 2020] @fdezdelarrea et al. @BCD_AACR https://t.co/esbt9qW3V6 #mmsm #CARTcell #c
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma $BMY $JUNO https://t.co/SERGUT0Q3n
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma {in mice} [Sep 2020] @fdezdelarrea et al. @BCD_AACR https://t.co/esbt9qW3V6 #mmsm #CARTcell #c
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
RT @Abdallah81MD: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Es…
RT @Abdallah81MD: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Es…
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma #mmsm https://t.co/5HJfr398nJ
RT @mtmdphd: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–…
@curious30525151 @fdezdelarrea @BCD_AACR Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma {in mice} [Sep 2020] @fdezdelarrea et al. @BCD_AACR ht
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma {in mice} [Sep 2020] @fdezdelarrea et al. @BCD_AACR https://t.co/MzwxZu5J97 #mmsm #CARTcell #ca
RT @OPENoncology: "We demonstrate, using murine models, that simultaneous dual-targeting of BCMA and GPRC5D antigens with CAR T-cell therap…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
"We demonstrate, using murine models, that simultaneous dual-targeting of BCMA and GPRC5D antigens with CAR T-cell therapy can prevent BCMA-escape–mediated relapse, as well as treat established BCMA-negative disease." @fdezdelarrea https://t.co/tUV5H6GdZ2
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @malinhultcrantz: Congrats @fdezdelarrea and @ESmithMDPhD! https://t.co/lpvDfvE1MP
RT @Transplant_Doc: Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Mu…
Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple #Myeloma #CARTcell #cellrx #mmsm #bmtsm https://t.co/xZAcF3zYyG @ESmithMDPhD @fdezdelarrea
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
RT @fdezdelarrea: On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Bl…
Congrats @fdezdelarrea and @ESmithMDPhD!
On the cover! Our article https://t.co/C43d8X06Pw about bispecific CAR T against BCMA plus GPRC5D (with editorial!) in Blood Cancer Discovery already online @BCD_AACR @ESmithMDPhD @sloan_kettering https://t.co/o9SxzaYRlU
RT @BCD_AACR: Speaking at #AACRLYMP20: Renier Brentjens, author of the recently published paper "Defining an Optimal Dual-Targeted CAR T-c…
Speaking at #AACRLYMP20: Renier Brentjens, author of the recently published paper "Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma." https://
RT @HiraSMian: Hoping for more durable responses #Myeloma with these novel approaches https://t.co/nt6jlLlWno
Don't miss @BCD_AACR author Renier Brentjens as he moderates this session on Tuesday. Read his recently published article> https://t.co/5DB0LPURYm
RT @BCD_AACR: ICYMI: In the Spotlight—Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. @fredhutch #CARTcell htt…
RT @BCD_AACR: ICYMI: In the Spotlight—Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. @fredhutch #CARTcell htt…
ICYMI: In the Spotlight—Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. @fredhutch #CARTcell https://t.co/HJDRqNgI07 Based on a Research Brief by Carlos Fernández de Larrea, et al. @fdezdelarrea https://t.co/2EW2DEWWJu https
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @BCD_AACR: Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. b…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @BCD_AACR: Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. b…
RT @BCD_AACR: Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. b…
RT @BCD_AACR: Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. b…
RT @BCD_AACR: Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. b…
RT @BCD_AACR: Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. b…
RT @BCD_AACR: Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. b…
Just published #OnlineFirst: In The Spotlight- Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple Myeloma. bcd@fredhutch #CARTcell https://t.co/jA20JsS73X Based on a Research Brief by Carlos Fernández de Larrea, et al. @fdezdelarrea http
RT @_TanyaBondar_: Just published in @BCD_AACR: A new commentary by Sylvain Simon and Stanley Riddell @fredhutch on #CARTcell design strate…
RT @_TanyaBondar_: Just published in @BCD_AACR: A new commentary by Sylvain Simon and Stanley Riddell @fredhutch on #CARTcell design strate…
Just published in @BCD_AACR: A new commentary by Sylvain Simon and Stanley Riddell @fredhutch on #CARTcell design strategies targeting two cancer antigens https://t.co/kn68YqzY1a. It is based on this research article: https://t.co/ieBu0WTJT2. https://t.co
RT @celltherapynews: Scientists from @sloan_kettering suggest that expressing two #ChimericAntigenReceptors (CARs) on a single cell enhance…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @celltherapynews: Scientists from @sloan_kettering suggest that expressing two #ChimericAntigenReceptors (CARs) on a single cell enhance…
Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Multiple Myeloma | Blood Cancer Discovery https://t.co/9FRtLEA7f6
RT @Abdallah81MD: Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Es…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @celltherapynews: Scientists from @sloan_kettering suggest that expressing two #ChimericAntigenReceptors (CARs) on a single cell enhance…
Scientists from @sloan_kettering suggest that expressing two #ChimericAntigenReceptors (CARs) on a single cell enhanced the strength of CAR T-cell/target cell interactions. https://t.co/o7aa14m0ia https://t.co/9CBw17EZQs
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @NicoGagelmann: Stimulating work targeting BCMA/GPRC5D by @fdezdelarrea @ESmithMDPhD et al.. will be interesting to see clinical efficac…
RT @CHM_MSKCC: Now #OnlineFirst! @BCD_AACR | @ESmithMDPhD @LabWendel @BrentjensRenier & colleagues @sloan_kettering | Define dual-targete…
Stimulating work targeting BCMA/GPRC5D by @fdezdelarrea @ESmithMDPhD et al.. will be interesting to see clinical efficacy compared with other multi-target CARTs in #myeloma @BCD_AACR @MM_Hub https://t.co/PlzeuGtNq7
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @fdezdelarrea: So glad that our article is now online! Amazing experience as visiting investigator in NYC. Thanks a lot! @ESmithMDPhD @s…
RT @ESmithMDPhD: Out in @BCD_AACR! Congrats @fdezdelarrea and all our collaborators for impressive work investigating dual-targeted CAR T c…
RT @MichaelodwyerMD: Congratulations @fdezdelarrea Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting…
RT @Transplant_Doc: Dual-Targeted CAR T-cell Therapy Simultaneously Targeting #BCMA and GPRC5D to Prevent BCMA Escape–Driven Relapse in Mu…